This program is a subset of the Drug Diversion, Poison Center, Opioid Treatment Program and Survey of Key Informants’ Patients program. Cases are defined as follows:

• In the Drug Diversion Program, cases are defined as diversion cases identified by regulatory agencies which include medical boards, pharmacy boards, dental boards, and nursing boards. These agencies specialize in the detection, treatment, and sanctioning of impaired health care workers who are involved in the diversion of prescription pharmaceuticals.
• In the Poison Center Program, cases are defined as intentional exposures with documentation in the case notes that the individual exposed is a health care worker.
• In the Opioid Treatment Program Program, cases are defined as self-reported use of a prescription or illicit opioid to get high in the past 30 days by respondents who self-identify as health care workers on the questionnaire.
• In the Survey of Key Informants’ Patients Program, cases are defined as self-reported use of a prescription or illicit opioid to get high in the past 30 days by respondents who self-identify as health care workers on the questionnaire.

This study is conducted by Richard C. Dart, M.D., Ph.D. at the Rocky Mountain Poison and Drug Center (RMPDC), a division of Denver and Hospital Authority (DHHA), in Denver, CO, in addition to the principal investigators of all signal detection programs. Other key study personnel include Ryan Westberry, M.S., M.B.A (Business Manager – Operations).